Lauren Amable

1.6k total citations · 2 hit papers
19 papers, 1.3k citations indexed

About

Lauren Amable is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Lauren Amable has authored 19 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Lauren Amable's work include Epigenetics and DNA Methylation (5 papers), Hedgehog Signaling Pathway Studies (4 papers) and DNA Repair Mechanisms (2 papers). Lauren Amable is often cited by papers focused on Epigenetics and DNA Methylation (5 papers), Hedgehog Signaling Pathway Studies (4 papers) and DNA Repair Mechanisms (2 papers). Lauren Amable collaborates with scholars based in United States, Sweden and United Kingdom. Lauren Amable's co-authors include Matthew D. Hall, Katie Spielbauer, Aaron E. Rusheen, Andrew Breglio, Katharine Fernandez, Lisa L. Cunningham, Richard E. Honkanen, Lalita A. Shevde, Elaine Gavin and Patrick Van Roey and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Lauren Amable

18 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin resistance and opportunities for precision medicine

2016 485 citations Lauren Amable Pharmacological Research profile →
Cisplatin is retained in the cochlea indefinitely following chemotherapy

2017 290 citations Andrew Breglio, Aaron E. Rusheen et al. Nature Communications profile →

Peers

Countries citing papers authored by Lauren Amable

Since Specialization

Citations

This map shows the geographic impact of Lauren Amable's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lauren Amable with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lauren Amable more than expected).

Fields of papers citing papers by Lauren Amable

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lauren Amable. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lauren Amable. The network helps show where Lauren Amable may publish in the future.

Co-authorship network of co-authors of Lauren Amable

This figure shows the co-authorship network connecting the top 25 collaborators of Lauren Amable. A scholar is included among the top collaborators of Lauren Amable based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lauren Amable. Lauren Amable is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Vitamin D₃ enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk 2019 ·Cancer Medicine ·(unknown), Yingyu Ma, Kristopher Attwood, Lauren Amable, Wei Luo, Carl Morrison, Khurshid A. Guru, Anna Woloszynska‐Read, Pamela A. Hershberger, Donald L. Trump, Candace S. Johnson	10
2	Cisplatin is retained in the cochlea indefinitely following chemotherapy breakdown → 2017 ·Nature Communications ·Andrew Breglio, Aaron E. Rusheen, (unknown), Katharine Fernandez, Katie Spielbauer, (unknown), Matthew D. Hall, Lauren Amable, Lisa L. Cunningham	290
3	ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming 2017 ·Journal of Clinical Investigation ·Prachi Mishra, Wei Tang, Vasanta Putluri, Tiffany H. Dorsey, Feng Jin, Fang Wang, (unknown), Lauren Amable, Tao Deng, Shaofei Zhang, J. Keith Killian, Yonghong Wang, Tsion Z. Minas, Harry G. Yfantis, Dong Hoon Lee, Arun Sreekumar, Michael Bustin, Wei Liu, Nagireddy Putluri, Stefan Ambs	65
4	Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer 2016 ·Clinical Cancer Research ·Jung Min Lee, Cody J. Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M. Annunziata, Nicole Houston, Andrew K.L. Goey, Tristan M. Sissung, (unknown), Lori M. Minasian, Victoria L. Chiou, Robert F. Murphy, Brigitte C. Widemann, William D. Figg, Elise C. Kohn	47
5	Cisplatin resistance and opportunities for precision medicine breakdown → 2016 ·Pharmacological Research ·Lauren Amable	485
6	PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells 2016 ·Oncotarget ·Winson S. Ho, Michael J. Feldman, Dragan Maric, Lauren Amable, Matthew D. Hall, Gerald M. Feldman, Abhik Ray‐Chaudhury, Martin J. Lizak, Juan C. Vera, Aaron Robison, Zhengping Zhuang, John D. Heiss	28
7	Abstract 3873: Single cell cisplatin measurements by ICP-MS 2016 ·Cancer Research ·Lauren Amable, Stan Smith, Chady Stephan	1
8	Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug 2014 ·Oncology Reports ·Lauren Amable, (unknown), Elaine Gavin, Eddie Reed	19
9	GLI1 upregulates C-JUN through a specific 130-kDa isoform 2013 ·International Journal of Oncology ·Lauren Amable, Elaine Gavin, Kenji Kudo, Erhong Meng, Rodney P. Rocconi, Lalita A. Shevde, Eddie Reed	11
10	Serine/threonine protein phosphatase 5 regulates glucose homeostasis in vivo and apoptosis signalling in mouse pancreatic islets and clonal MIN6 cells 2012 ·Diabetologia ·Nina Grankvist, Lauren Amable, Richard E. Honkanen, Åke Sjöholm, Henrik Ortsäter	16
11	Calcineurin Regulates Homologous Desensitization of Natriuretic Peptide Receptor-A and Inhibits ANP-Induced Testosterone Production in MA-10 Cells 2012 ·PLoS ONE ·(unknown), (unknown), Bing Zhu, Lauren Amable, Richard E. Honkanen, Jackie D. Corbin, Sharron H. Francis, Thomas C. Rich	6
12	Abstract 5613: A specific isoform of Gli1 binds the Gli-binding site of the c-jun and c-fos promoters 2012 ·Cancer Research ·Lauren Amable, Elaine Gavin, Wesley B. Denny, Erhong Meng, Rodney P. Rocconi, Eddie Reed	0
13	Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum–DNA adduct repair 2012 ·Oncogene ·Kenji Kudo, Elaine Gavin, Subhadeep Das, Lauren Amable, Lalita A. Shevde, E Reed	53
14	Disruption of Serine/Threonine Protein Phosphatase 5 (PP5:PPP5c) in Mice Reveals a Novel Role for PP5 in the Regulation of Ultraviolet Light-induced Phosphorylation of Serine/Threonine Protein Kinase Chk1 (CHEK1) 2011 ·Journal of Biological Chemistry ·Lauren Amable, Nina Grankvist, (unknown), Henrik Ortsäter, Åke Sjöholm, Richard E. Honkanen	31
15	Structure-Activity Relationship Studies of Fostriecin, Cytostatin, and Key Analogs, with PP1, PP2A, PP5, and (β12–β13)-Chimeras (PP1/PP2A and PP5/PP2A), Provide Further Insight into the Inhibitory Actions of Fostriecin Family Inhibitors 2009 ·Journal of Pharmacology and Experimental Therapeutics ·Mark R. Swingle, Lauren Amable, Brian G. Lawhorn, Suzanne B. Buck, Christopher P. Burke, (unknown), (unknown), Dale L. Boger, Richard E. Honkanen	48
16	Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer 2008 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Teresa Golden, Ileana Aragon, (unknown), J. Allan Tucker, Lalita A. Shevde, Rajeev S. Samant, Guofei Zhou, Lauren Amable, Danalea V. Skarra, Richard E. Honkanen	49
17	Investigations into the Structure‐Activity Relationship of Fostriecin, a Potent Inhibitor of Ser/Thr Protein Phosphatases 2006 ·The FASEB Journal ·Lauren Amable, (unknown), Mark R. Swingle, (unknown), (unknown), Dale L. Boger, Richard E. Honkanen	2
18	Total Synthesis and Evaluation of Cytostatin, Its C10−C11 Diastereomers, and Additional Key Analogues: Impact on PP2A Inhibition 2006 ·Journal of the American Chemical Society ·Brian G. Lawhorn, (unknown), S. E. Wolkenberg, David A. Colby, Carla‐Maria Gauss, Mark R. Swingle, Lauren Amable, Richard E. Honkanen, Dale L. Boger	46
19	Family 18 chitinase–oligosaccharide substrate interaction: subsite preference and anomer selectivity of Serratia marcescens chitinase A 2003 ·Biochemical Journal ·Nathan N. Aronson, Brian Halloran, (unknown), Lauren Amable, Jeffry D. Madura, (unknown), (unknown), Patrick Van Roey	87

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact